NASDAQ:BTMD biote (BTMD) Stock Price, News & Analysis → Bombshell 2024 election documentary (From Porter & Company) (Ad) Free BTMD Stock Alerts $5.80 -0.07 (-1.19%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$5.79▼$6.1350-Day Range$3.79▼$6.9152-Week Range$3.65▼$8.22Volume170,951 shsAverage Volume140,601 shsMarket Capitalization$432.29 millionP/E RatioN/ADividend YieldN/APrice Target$8.11 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get biote alerts: Email Address biote MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside39.8% Upside$8.11 Price TargetShort InterestBearish2.27% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.29Based on 3 Articles This WeekInsider TradingN/AProj. Earnings Growth48.72%From $0.39 to $0.58 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.39 out of 5 starsMedical Sector552nd out of 939 stocksMedicinals & Botanicals Industry4th out of 11 stocks 3.5 Analyst's Opinion Consensus Ratingbiote has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.11, biote has a forecasted upside of 39.8% from its current price of $5.80.Amount of Analyst Coveragebiote has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.27% of the float of biote has been sold short.Short Interest Ratio / Days to Coverbiote has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in biote has recently increased by 28.83%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend Yieldbiote does not currently pay a dividend.Dividend Growthbiote does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BTMD. Previous Next 1.8 News and Social Media Coverage News Sentimentbiote has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for biote this week, compared to 1 article on an average week.MarketBeat FollowsOnly 2 people have added biote to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, biote insiders have not sold or bought any company stock.Percentage Held by Insiders16.60% of the stock of biote is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 21.68% of the stock of biote is held by institutions. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for biote are expected to grow by 48.72% in the coming year, from $0.39 to $0.58 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of biote is -26.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of biote is -26.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyBombshell 2024 election documentary 2024: America’s Last Election New documentary reveals why this could be America’s Last Election… and how the elites’ plan threatens to reset the entire U.S. economy, along with your 401(k), bank, and stock portfolio.All the facts are here. About biote Stock (NASDAQ:BTMD)biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.Read More BTMD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BTMD Stock News HeadlinesMarch 25, 2024 | msn.comEsperion stock jumps 18% in wake of FDA label expansionsMarch 18, 2024 | markets.businessinsider.comPharvaris Buy Rating Affirmed Amid Promising Phase 3 HAE Trial ProspectsMarch 29, 2024 | Porter & Company (Ad)Bombshell 2024 election documentary 2024: America’s Last Election New documentary reveals why this could be America’s Last Election… and how the elites’ plan threatens to reset the entire U.S. economy, along with your 401(k), bank, and stock portfolio.March 14, 2024 | marketwatch.comBiote Soars 22% With Expected Acceleration in 2H 2024 SalesMarch 13, 2024 | finance.yahoo.combiote Corp. (PNK:BTMD) Q4 2023 Earnings Call TranscriptMarch 12, 2024 | finance.yahoo.comBiote Corp (BTMD) Reports Growth Amidst Challenges in Q4 and Full Year 2023March 12, 2024 | businesswire.comBiote Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 11, 2024 | benzinga.comPreview: Biote's EarningsMarch 29, 2024 | Porter & Company (Ad)Bombshell 2024 election documentary 2024: America’s Last Election New documentary reveals why this could be America’s Last Election… and how the elites’ plan threatens to reset the entire U.S. economy, along with your 401(k), bank, and stock portfolio.February 27, 2024 | finance.yahoo.comBiote Schedules Fourth Quarter and Full Year 2023 Financial Results Release and Conference CallFebruary 27, 2024 | businesswire.comBiote Schedules Fourth Quarter and Full Year 2023 Financial Results Release and Conference CallFebruary 20, 2024 | msn.comBiote announces agreement to resolve litigation with founder Gary DonovitzFebruary 20, 2024 | finance.yahoo.comBiote Announces Agreement to Resolve Litigation and Repurchase All of Founder’s SharesFebruary 20, 2024 | businesswire.comBiote Announces Agreement to Resolve Litigation and Repurchase All of Founder's SharesJanuary 25, 2024 | finance.yahoo.comBiote Announces $20 Million Share Repurchase AuthorizationJanuary 20, 2024 | benzinga.comBiote Stock (NASDAQ:BTMD), Analyst Ratings, Price Targets, PredictionsJanuary 18, 2024 | bizjournals.comBirmingham manufacturer to be acquired for $8.5MJanuary 18, 2024 | realmoney.thestreet.comBiote price target lowered by $1 at Truist, here's whyJanuary 11, 2024 | msn.comBiote names Robert Peterson as its CFOJanuary 11, 2024 | markets.businessinsider.comBiote Names Robert Peterson CFOJanuary 11, 2024 | finance.yahoo.comBiote Names Robert Peterson as Chief Financial OfficerNovember 30, 2023 | seekingalpha.combiote Should Keep Delivering Strong GrowthNovember 8, 2023 | msn.comDurect, Lumos Pharma among healthcare moversNovember 8, 2023 | msn.comBIOTE GAAP EPS of $0.24, revenue of $45.6MNovember 8, 2023 | finance.yahoo.comBiote Corp. (BTMD) Reports Q3 Loss, Lags Revenue EstimatesNovember 7, 2023 | finance.yahoo.comBiote Reports Third Quarter 2023 Financial ResultsNovember 5, 2023 | morningstar.comBiote Corp BTMDSee More Headlines Receive BTMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for biote and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/10/2023Today3/29/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medicinals & botanicals Sub-IndustryN/A Current SymbolNASDAQ:BTMD CUSIPN/A CIK1819253 Webbiote.com Phone844-604-1246Fax212-616-9601Employees194Year FoundedN/APrice Target and Rating Average Stock Price Target$8.11 High Stock Price Target$9.00 Low Stock Price Target$6.55 Potential Upside/Downside+39.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.22) Trailing P/E RatioN/A Forward P/E Ratio14.87 P/E GrowthN/ANet Income$3.32 million Net Margins1.79% Pretax Margin-0.07% Return on Equity-45.10% Return on Assets19.61% Debt Debt-to-Equity RatioN/A Current Ratio5.51 Quick Ratio4.73 Sales & Book Value Annual Sales$185.36 million Price / Sales2.33 Cash Flow$0.49 per share Price / Cash Flow11.85 Book Value($0.58) per share Price / Book-10.00Miscellaneous Outstanding Shares74,530,000Free Float62,160,000Market Cap$432.27 million OptionableNot Optionable Beta0.88 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Marc D. Beer (Age 59)Executive Chairman Comp: $484kMs. Teresa S. Weber (Age 71)CEO & Director Comp: $3.7MMs. Mary Elizabeth Conlon (Age 43)VP of Business Development, General Counsel & Corporate Secretary Comp: $475kMr. Robert PetersonChief Financial OfficerMr. Joe Butler (Age 62)Chief Information Officer Mr. James Elliott Gibbs IIChief People OfficerMr. Richard Kevin Key (Age 53)Chief Digital Officer Mr. Jade Beutler (Age 61)Head of Nutraceuticals Dr. Ross W. McQuivey M.D. (Age 52)Chief Medical Officer & Member of Medical Advisory Board Dr. Cory Rice D.O.Chief Clinical Advisor & Member of Medical Advisory BoardMore ExecutivesKey CompetitorsMind Medicine (MindMed)NASDAQ:MNMDDecarbonization Plus Acquisition Co. IVNASDAQ:DCRDCanopy GrowthNASDAQ:CGCAdTheorentNASDAQ:ADTHChromaDexNASDAQ:CDXCView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 394,991 shares on 3/11/2024Ownership: 1.951%Vanguard Group Inc.Bought 394,991 shares on 2/15/2024Ownership: 1.951%Barclays PLCBought 15,015 shares on 2/15/2024Ownership: 0.054%SW Investment Management LLCBought 22,651 shares on 2/14/2024Ownership: 0.928%Royal Bank of CanadaSold 2,575 shares on 2/14/2024Ownership: 0.025%View All Insider TransactionsView All Institutional Transactions BTMD Stock Analysis - Frequently Asked Questions Should I buy or sell biote stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for biote in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BTMD shares. View BTMD analyst ratings or view top-rated stocks. What is biote's stock price target for 2024? 5 analysts have issued 1-year target prices for biote's shares. Their BTMD share price targets range from $6.55 to $9.00. On average, they predict the company's stock price to reach $8.11 in the next twelve months. This suggests a possible upside of 39.8% from the stock's current price. View analysts price targets for BTMD or view top-rated stocks among Wall Street analysts. How have BTMD shares performed in 2024? biote's stock was trading at $4.94 on January 1st, 2024. Since then, BTMD shares have increased by 17.4% and is now trading at $5.80. View the best growth stocks for 2024 here. Are investors shorting biote? biote saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 754,400 shares, an increase of 28.8% from the February 29th total of 585,600 shares. Based on an average daily volume of 107,300 shares, the short-interest ratio is presently 7.0 days. Currently, 2.3% of the company's stock are short sold. View biote's Short Interest. When is biote's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our BTMD earnings forecast. How were biote's earnings last quarter? biote Corp. (NASDAQ:BTMD) posted its quarterly earnings results on Thursday, August, 10th. The company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $0.34. The company had revenue of $49.26 million for the quarter, compared to analyst estimates of $46.76 million. biote had a net margin of 1.79% and a negative trailing twelve-month return on equity of 45.10%. During the same quarter in the previous year, the firm earned $0.27 earnings per share. What guidance has biote issued on next quarter's earnings? biote issued an update on its FY 2024 earnings guidance on Tuesday, March, 12th. The company provided EPS guidance of for the period. The company issued revenue guidance of $200.0 million-$204.0 million, compared to the consensus revenue estimate of $203.2 million. Who are biote's major shareholders? biote's stock is owned by many different retail and institutional investors. Top institutional shareholders include Bandera Partners LLC (2.52%), Vanguard Group Inc. (1.95%), Vanguard Group Inc. (1.95%), Wasatch Advisors LP (1.47%), Boston Partners (1.14%) and SW Investment Management LLC (0.93%). Insiders that own company stock include Mary Elizabeth Conlon, Roystone Capital Management Lp and Samar Jagat Kamdar. View institutional ownership trends. How do I buy shares of biote? Shares of BTMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BTMD) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeYour Money is Not SafeAmerican AlternativeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaThe ONE AI Sock to own now. (It’s not Nvidia.)Weiss Ratings“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding biote Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.